Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook
7.12.2020 13:09:00 EET | Business Wire | Press release
Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook. With over 26 years’ experience partnering with start-up to mid-size biotech and pharmaceutical companies, Veristat excels in supporting complex trials across a wide range of therapeutic areas. Always taking a patient-centric approach, the company is highly innovative and formulates flexible solutions that benefit patients and attract them to participate in clinical trials.
“In today’s digital world, patients proactively participate in their health plans and seek information on various diseases and treatments online,” stated Shaheen Limbada, Executive Vice President, Global Clinical Operations at Veristat, “Realizing this, we’ve focused on targeting the potential and intended participants for trials through digital media and online platforms. Veristat curates highly relevant and appropriate patient populations by leveraging in-house, customized marketing, and search engine optimization strategies. These strategies improve patient recruitment and retention success rates for trials efficiently and cost-effectively.”
Responding rapidly to the COVID-19 situation and taking a thoughtful scientific approach towards it, Veristat has expanded virtual ecosystems for clients specific to their needs ensuring continuity of ongoing and new clinical trials. The company has developed a “rescue study methodology,” comprised of a series of non-conventional good clinical practice (GCP) compliant tactics for supporting trials. By setting up virtual sites, Veristat ensures the continuity of studies by allowing patients to participate in trials remotely through telemedicine patient portals and at-home visits. Access to the required equipment and medical supplies promptly enabled patients to continue the programs and clients to begin new programs. The company safeguarded patient recruitment throughout the pandemic with its rescue strategies. This included web console technology for staff to interact, patient portals for patients and physicians to communicate via telemedicine, and secure document exchange portals for the collection of study documentation.
Applying knowledge from the various COVID-19 trials that they have conducted, Veristat established a COVID taskforce to centralize the lessons learned and to leverage the most successful approaches on the different trials to focus the trial activities to achieve the highest enrollment. “We are continuously working on advancing the trials in a productive and impactful way unique for each clinical setting to ensure we respond to a highly elevated sense of urgency due to the pandemic and evolving client needs,” stated Patrick Flanagan, Chief Executive Officer at Veristat.
Click here for access to the full interview on Pharma Tech Outlook.
About Veristat:
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, cell and gene therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005104/en/
Contact information
Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 11:30:00 EEST | Press release
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001835078/en/ Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories. This agreement reinforces the long-standing and successful
FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 11:00:00 EEST | Press release
FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam
Telekom Srbija (Group) Is Building City-Scale Digital Infrastructure for EXPO 20271.10.2026 11:00:00 EEST | Press release
Telekom Srbija Group is building telecommunications infrastructure at the EXPO 2027 Belgrade site whose mobile segment is comparable in scale to that of an entire urban district. On a site that previously had no telecommunications infrastructure, more than 14 kilometres of telecommunications ducting and over 46 kilometres of high-capacity fibre-optic network have been delivered so far, together with 35 advanced radio access network sites. The digital ecosystem, based on 5G Standalone and Wi-Fi 7 technologies, is designed to provide reliable, secure and high-speed connectivity for more than 135 participating countries, the media, exhibitors and the four million visitors expected over the 93 days of EXPO 2027. For Telekom Srbija Group, however, this project is more than an infrastructure undertaking. As a strategic partner of EXPO 2027, the company intends to use one of the largest international events ever held in Serbia as a platform for presenting its technological capabilities and bu
ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform1.10.2026 10:30:00 EEST | Press release
ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience to develop its enterprise-grade digital offering that automates these services. The technology has been live in production for years, bundled with ROYC's services with more than 20 fund managers operating drawdown and evergreen funds on the ROYC OS, distributing to over 50 banks and wealth managers. “We saw where legacy solutions were failing fund managers: spreadsheets and software assembled from separate tools bolted together over time, with no single record connecting a fund to its service providers and investors,” said Octavian Popescu, Co-Founder and CEO of ROYC Group. “We built ROYC OS the other way aroun
Eaton vahvistaa eurooppalaista tuotantoaan laajentamalla tuotantolaitostaan Itävallassa1.10.2026 10:00:00 EEST | Tiedote
Eaton juhlistaa Itävallassa sijaitsevan Schremsin tuotantolaitoksensa laajennusta 1. lokakuuta 2026. Laajennus vastaa sähköistymisen ja digitalisaation kasvattamaan kysyntään kaikkialla Euroopassa sekä lisää sähköisten suojaus- ja sähkönhallintaratkaisujen alueellista tuotantokapasiteettia. Alle kymmenessä kuukaudessa valmistunut laajennus yhdistää täysin automatisoidun tuotannon, edistyneen digitaalisen integraation ja tuotteiden end-to-end -jäljitettävyyden. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261001549090/fi/ Eaton expanded manufacturing capacity in Europe for power management solutions in Schrems, Austria. ”Asiakkaat investoivat kaikkialla Euroopassa kriittiseen infrastruktuuriin, joka pitää yritykset toiminnassa, tukee talouskasvua ja vastaa kasvavaan sähkön kysyntään. Tämä laajennus kuvastaa jatkuvia investointejamme tuotantoon, teknologiaan ja osaavaan työvoimaan. Samalla se lisää niiden tuotteiden ja ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
